A Monash University study has revealed that walking speed (gait) and grip strength could be early indicators of dementia before the onset of other more noticeable symptoms.
The researchers found slow walking speed combined with weak hand grip was a stronger predictor of cognitive decline and dementia in older adults than either measure alone.
Lead author Dr Suzanne Orchard, Senior Research Fellow with Monash University’s School of Public Health and Preventive Medicine says this research shows an important link between age-related cognitive decline and physical decline.
“Poor physical function may be a marker of future risk of cognitive decline and dementia, and thus, understanding this association could enhance early detection and prevention strategies,” Dr Orchard said.
“While there are currently no cures for dementia, if identified early, treatment strategies can be implemented to slow its progression and manage the symptoms.”
Dr Orchard says there is an opportunity for healthcare providers, like community pharmacies, to offer grip strength and gait speed assessments that could help identify dementia risk early and establish treatment pathways to improve patient outcomes.
The study
The study of data from more than 18,000 initially healthy adults, mostly aged 70 and older in the ASPREE trial, revealed that a combined poor gait speed and grip strength was linked to a 79% increased risk of dementia and a 43% increased risk of cognitive decline.
Over time, the risk for dementia or cognitive decline was shown to be highest when gait and grip declined simultaneously over the study period of nearly 5 years, with an 89% increased risk of dementia and 55% increased risk of cognitive decline.
Participants’ grip strength and gait speed were measured upon entry to ASPREE and repeated for an average of 4.7 years.
Gait speed was timed by walking at a normal pace over a distance of three metres, while grip strength was assessed using a hand-held device to measure force.
Researchers then compared these physical benchmarks against participants’ cognition, measured using assessments that examine functions such as memory and processing speed.
It’s the first time the two physical measures have been studied together to assess their combined link with changes in cognitive function.
During the course of the ASPREE trial, 2773 participants in this analysis developed cognitive decline and 558 dementia.
The findings have significant implications for dementia diagnosis, early intervention and treatment.
Globally, the number of people living with dementia is expected to almost triple in three decades, from 57.4 million in 2019 to 152.8 million by 2050.
